

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

NCT06926192

Status RECRUITING
Sponsor Peking Union Medical College
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
- The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
- Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
- Patients with complete clinical data followed up for at least 1 year

Exclusion (3)

- Patients lost to follow-up
- Patients with less than one year of follow-up
- Patients who received additional adjuvant therapy during the follow-up period

Locations (1 total)

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu, China